Carl Jack Fichtenbaum MD

Infectious Disease•Cincinnati, OH

HIV/AIDS Medicine

Professor of Medicine, University Cincinnati

Join to View Full Profile

200 Albert Sabin Way405Cincinnati, OH 45267
Phone+1 513-584-6977
Fax+1 513-584-6040

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Infectious Disease, 1991 - 1994
Yale-New Haven Medical CenterFellowship, Infectious Disease, 1990 - 1991
Bridgeport Hospital/Yale UniversityResidency, Internal Medicine, 1985 - 1990
University of Missouri Kansas City School of MedicineClass of 1985

Certifications & Licensure

OH State Medical License 1999 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

A Study of Nitazoxanide in Patients With AIDS and Diarrhea Caused by Cryptosporidium
Completed
Phase 2
DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP) Start of enrollment: 2006 May 01
Terminated
Phase 3
HIV Screening in the Emergency Department Setting Start of enrollment: 2008 Jan 01
Completed
Not Applicable
Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study Start of enrollment: 2009 Jan 01
Completed
Phase 1, Phase 2
Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection Start of enrollment: 2005 Oct 01
Completed
Phase 4
Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery Start of enrollment: 2014 Jul 02
COMPLETED
PHASE2
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection Start of enrollment: 2014 May 30
Completed
Phase 1
Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure Start of enrollment: 2014 Dec 01
Completed
Phase 3
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART) Start of enrollment: 2015 Dec 21
Completed
Phase 1, Phase 2
A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV Start of enrollment: 2023 May 30
COMPLETED
PHASE2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Statin effects on the incidence of major non-cardiovascular disease events among a global cohort of people with HIV: a randomised controlled trial.
Marissa R Diggs, Triin Umbleja, Sara McCallum, Markella V Zanni, Sarah M Chu
The Lancet. HIV. 2025-04-01
Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV: A Secondary Analysis of the REPRIEVE Randomized Clinical Trial.
Márton Kolossváry, Samuel R Schnittman, Markella V Zanni, Kathleen V Fitch, Carl J Fichtenbaum
JAMA Cardiology. 2025-03-01
Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection.
Myra Happe, Rebecca M Lynch, Carl J Fichtenbaum, Sonya L Heath, Susan L Koletar
JCI Insight. 2025-02-24

Journal Articles

Safety and Impact of Low-Dose Methotrexate on Endothelial Function and Inflammation in Individuals with Treated Human Immunodeficiency Virus: AIDS Clinical Trials Grou...
Steven G Deeks, James H Stein, Carl Fichtenbaum, Judith S Currier, Priscilla Y Hsue, Eric S Daar, Ahmed Tawakol, Michael Lederman, Tanvir Bell, Diane Havlir, Clinical Infectious Diseases

Press Mentions

What Does It Mean to Be Immunocompromised?October 10th, 2024
Here’s How the End of the COVID-19 Public Health Emergency Could Affect You, According to MDsFebruary 14th, 2023
'It's Happening a Little Bit Earlier.' Flu Hospitalizations Rise in Southwest OhioNovember 10th, 2022
Join now to see all

Grant Support

University Of Cincinnati AIDS Clinical Trials Unit- UC ActuNational Institute Of Allergy And Infectious Diseases2008–2012
HIV Protease Inhibitors And Calcium Channel BlockersNational Center For Research Resources2004
ACTG A5108 Efavirenz/Nelfinavir StudyNational Center For Research Resources2004
Epidemiology And Outcome Of STDS In Drug UsersNational Institute On Drug Abuse1999
Washu55--Orally Administered SP 303 Treatment Of Diarrhea Aids--37, 554National Center For Research Resources1999
Epidemiology And Outcome Of STDS In Drug UsersNational Institute On Drug Abuse1996–1998